Tom Malinowski bought Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC)
Tom Malinowski (D-NJ), a U.S. Representative, has disclosed 4 trades in Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC) since 2019, 2 purchases and 2 sales, worth an estimated $32K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Tom Malinowski bought $1,001 - $15,000 of Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC) on November 13, 2019. Since that trade, TRHC is up +0.00% against the S&P 500 up +163.86%, an outperformance of -163.86%.
Across these filings, Tom Malinowski has been a balanced trader of TRHC (a buy-to-sell ratio of 1.00). Each row in the table below links to that trade and its post-trade performance versus the market.
Data updated
Tom Malinowski's TRHC trades vs the price
TRHC is up +0.00% since Tom Malinowski bought on November 13, 2019, versus +163.86% for the S&P 500.
Performance since this trade
All Tom Malinowski TRHC trades
| Traded | Type | Size | Return | Est. profit | |
|---|---|---|---|---|---|
| November 13, 2019 | BUY | $1,001 - $15,000 | N/A | — | |
| November 12, 2019 | SELL | $1,001 - $15,000 | N/A | — | |
| November 8, 2019 | SELL | $1,001 - $15,000 | N/A | — | |
| November 7, 2019 | BUY | $1,001 - $15,000 | N/A | — |
Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.
Tom Malinowski & TRHC trading FAQ
Is it legal for Tom Malinowski to trade Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Tom Malinowski buy TRHC?
Tom Malinowski disclosed a purchase of $1,001 - $15,000 of Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC) on November 13, 2019, according to public STOCK Act filings.
How has TRHC performed since Tom Malinowski's trade?
Since Tom Malinowski bought TRHC on November 13, 2019, the stock is up +0.00%, versus +163.86% for the S&P 500 over the same period, an outperformance of -163.86%.
How many times has Tom Malinowski traded TRHC?
Tom Malinowski has disclosed 4 TRHC trades since 2019 (2 purchases and 2 sales). Every disclosed trade is listed on this page.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional TRHC trades?
Quantellect tracks every disclosed congressional trade in Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. (TRHC) on the Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200. congressional trading page, which aggregates filings across all members of Congress.
Tom Malinowski's TRHC tradesAll congressional filings for Tabula Rasa HealthCare, Inc. (TRHC) [ST] F IlINg S TATuS : Amended D ESCRIPTION : Short Cover Purchase. Capital gains Exceed $200.Tom Malinowski's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.